Novel chemothemotherapy for brain tumors using a nano-carrier combined with ICG

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10750
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Chiba University
• Principal Investigator: IWADATE Yasuo 千葉大学, 大学院医学研究院, 教授 (70272309)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: glioma / liposome / nanocarrier / chemotherapy / immune response / HSP70

Outline of Final Research Achievements

We have developed a liposome combined with indocyanine green (ICG) which specifically accumulates in a brain tumor model and generates heat and active oxygen when irradiated with infrared ray. We planned to use this particle as a nanocarrier enclosed with anticancer agents. A significant reduction in tumor progression was observed in the treated tumors, which was accompanied with a high expression of heat shock protein-70. This efficacy was also accompanied with CD-8 T cell accumulation and not observed in the immuno-compromised animals. However, enclosure of temozolomide did not generate an additional efficacy. It is supposed to be important in the treatment of brain tumors how effectively tie the tumor cell death to the induction of acquired immunity.

Free Research Field

脳神経外科

Academic Significance and Societal Importance of the Research Achievements

膠芽腫は希少疾患であるが、最も悪性度の高い脳腫瘍であり、50歳代に高頻度に発症するため社会的損失の大きい疾患である。血液脳関門(BBB)の存在により、薬剤移行性が不良でありその治癒を阻む一因となる。我々は、近赤外蛍光色素であるindocianine green (ICG) 結合型リポソームをナノキャリアとして用い、種々の抗がん剤をその中に封入し、腫瘍局所に高濃度に分布させることによって効率的に細胞死を誘導し、特異的抗腫瘍免疫が誘導されることを示した。